TRPV4/CaSR promotes the survival of GC via AKT/beta-catenin/Ca2+ pathway whereas TRPV4/VPAC1 promotes GC cell survival through the ERK1/2/Ca2+/JNK/beta-catenin pathway. Here, MAPK3 is linked to gastric cancer.